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investigated if the MTHFR C677T polymorphism modulates 
the risk of developing breast, rectal and lung cancer. 
Material and Methods  
Genotyping was performed by PCR-RFLP method on a 
sample of 103 patients diagnosed with histologically 
proven cancer (52 rectal, 26 lung, and 25 breast) and 186 
healthy controls, respectively (60, 101, 25)   
Results  
Analyses of affected and controls show that homozygote 
genotype MTHFR 677CC has the highest frequency in both 
groups in lung and rectal localization, it was 65.38% in 
patients and 45. 5% in control group in lung localization, 
48% in patients with rectal localization and 55% in control 
group. In breast localization the distribution of the CC, 
CT and TT genotypes corresponded respectively to the 
proportions 40%, 55% and 5%. The odds ratio for the TT 
and CT genotypes was 1.42 (95% CI = 0.42-4.85) and the 
odds ratio for the TT and CT genotypes was 1.26 (95% CI = 
0, 07-21, 49) and 0.69 (95% CI 0.21-2.29. We also 
demonstrated a modest increase in the risk of breast 
cancer in individuals with TT genotype compared to the 
general population (OR = 1.26; 95% CI = 0.07-21.49). 
Conclusion  
Despite the low rate of enrolled population in our study, 
we can conclude based on the results of our study that a 
significant association between lung, rectal cancer and 
C677T polymorphism might exist. 
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Purpose or Objective  
Stereotactic body radiation therapy (SBRT) is an effective 
treatment for patients with lung tumors (both primitive 
and secondary) who are not candidates for surgery. For 
patients treated with SBRT, there are relatively few 
studies that examined predictors of regional and/or 
distant progression and agreement among them is poor. 
As several studies have shown that the analysis of 
baseline F-FDG PET/CT features has predictive and 
prognostic significances in several types of cancers, 
including oropharyngeal, esophageal and sarcoma, we 
hypothesized that imaging-based features could identify 
patients with lung tumors treated with SBRT who are at 
highest risk for progression.  The aim of this study is to 
assess the prognostic impact and predictive role of the 
maximum standardized uptake value (SUV max), the 
metabolic tumor volume (MTV), the total lesion glycolysis 
(TLG) and SUV max lesion/SUVmax liver (rPET) and their 
correlation with  local control, overall survival (OS) and 
progression-free survival (PFS) in patients treated with 
stereotactic body radiation therapy (SBRT) for primitive 
or secondary lung tumors undergoing pretreatment [F-18] 
fluoro- D-glucose-positron emission tomography/ 
computed tomography (F-FDG PET/CT) imaging.  
Material and Methods  
Between September 2009 to December 2016, 70 patients 
with 85 medically inoperable lung tumors were treated 
with SBRT and underwent a F-FDG PET/CT before the 
treatment. Median age was 73 years. SBRT schedules 
were 60/55/50 Gy in 5 fractions or 54 Gy in 3 fractions.  
The effects of clinical-pathological factors including 
primary tumor SUV max, MTV, TLG and rPET on OS, PFS 
and local control (LC) were evaluated. Kaplan–Meier 
survival curves were produced and compared with the 
log-rank test.  
Results  
With a median follow-up  for the population of  26 
months,  the median OS and PFS were 39.7 and 30.1 
months, respectively.  The 12- and 24-months OS for the 
entire cohort  were  94%  and 76%, respectively , with a 
12- and 24-months PFS of 81% and 60%, respectively. On 
univariate analysis SUV max of tumor, (cut-off: 10), 
showed  a mild correlation with OS,  even if statistical 
significance has not been achieved (p= 0.611) (figure). 
 
Multivariate Cox analysis showed that non analysed 
 parameters were related to OS [(SUVmaX p: 0.446); TLG 
( p: 0.294); MTV (p:0.568)] and PFS [(SUVmax p: 0.648); 
TLG (p: 0.414); MTV (p: 0.981)]. Wilcoxon test showed 
that no correlation was observed between SUVmax (p: 
0.6988), MTV ( p: 0.6761), TLG (p: 0.8495), SUVmax 
tumor/SUV max liver ratio (rPET)  and local control.  
Conclusion  
The prognostic value of SUVmax and other PET related 
factors in patients with lung tumors remains controversial 
and many reports have indicated that it has positive or 
negative associations with outcome. In our study no 
significant association was found between SUVmax, MTV , 
TLG and rPET  and clinical outcomes such as OS, PFS or 
LC in patients affected by lung tumors treated with SBRT.  
 
EP-1366  Different toxicity rating patients and 
physicians in randomized phase III PCI vs obs stage III 
NSCLC 
D. De Ruysscher1, A. Dingemans2, J. Praag3, J. Belderbos4, 
C. Tissing-Tan5, G. Herder6, T. Haitjema7, F. Ubbels8, F. 
Lagerwaard9, J. Stigt10, E. Smit11, H. Van Tinteren12, V. 
Van der Noort12, H. Groen13 
1MAASTRO Clinic, Radiation Oncology, Maastricht, The 
Netherlands 
2Maastricht University Medical Center, Pulmonology, 
Maastricht, The Netherlands 
3Erasmus Medical Center, Radiation Oncology, 
Rotterdam, The Netherlands 
4Netherlands Cancer Institute, Radiation Oncology, 
Amsterdam, The Netherlands 
S746	  	   	   ESTRO	  37	  
	   	   	  
5Radiotherapeutic Institute Arnhem, Radiation Oncology, 
Arnhem, The Netherlands 
6Antonius hospital Nieuwegein, Pulmonology, 
Nieuwegein, The Netherlands 
7Medical Center Alkmaar, Pulmonology, Alkmaar, The 
Netherlands 
8University Medical Center Groningen, Radiation 
Oncology, Groningen, The Netherlands 
9Free University Medical Center, Radiation Oncology, 
Amsterdam, The Netherlands 
10Isala hospital Zwolle, Pulmonology, Zwolle, The 
Netherlands 
11Netherlands Cancer Institute, Pulmonology, 
Amsterdam, The Netherlands 
12Netherlands Cancer Institute, Statistics, Amsterdam, 
The Netherlands 
13University Medical Center Groningen, Pulmonology, 
Groningen, The Netherlands 
 
Purpose or Objective  
The NVALT-11/ DLCRG-02 randomized trial showed that 
PCI reduced the incidence of symptomatic brain 
metastases from 30.7 % to 8.1 %. Here, we report the 
differences between the adverse events (AE) reporting 
between patients and physicians. 
Material and Methods  
Randomization between PCI or observation in radically 
treated stage III NSCLC. Primary endpoint: incidence of 
symptomatic brain metastases; secondary endpoints: OS, 
AE reported by patients and physicians, QoL. 
Results  
175 patients were randomized, 87 PCI and 88 
observation.  
Patients reported AE: dizziness, headache, hypersomnia, 
memory impairment and vomiting. For patients, only 
grade 1-2 headache occurred significantly more 
frequently in the PCI group. Physicians reported AE 
occurring significantly more in the PCI arm: G1-2 memory 
impairment, cognitive disturbance, fatigue, headache, 
fatigue. 
Differences in AE reporting by patients and physicians: 
Table 1. Reported by the patient but not by the 
physician: Memory impairment in 40/88 (45 %) and in 
27/87 (31 %); fatigue in 40/88 (45 %) and in 27/87 (31 %); 
headache in 29/88 (33 %) and 28/87 (32 %) in the 
observation and PCI arms, respectively.   
Conclusion  
Many AEs were only reported by the patient; the results 
also may suggest physician bias in AE reporting. PROs 
should be part of outcome measurements.  
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Purpose or Objective  
Inflammation plays a central role in the development of 
both lung cancer and cardiovascular disease (CVD) and 
CVD is frequently seen in patients with non-small cell 
lung cancer (NSCLC).  Chronic inflammation is associated 
with an increased cell turnover with the potential of 
generating genetic errors, stimulate angio-neogenesis, 
and apoptosis and plays a role in the pathogenesis of CVD 
with an influence on all stages of the disease. We 
hypothesized that self-reported CVD is an independent 
risk factor for survival in lung cancer. Our hypothesis was 
studied in a prospective multicenter cohort study. 
Material and Methods  
Prospective multicenter data from 345 consecutive NSCLC 
patients that were seen in consultation in the radiation 
oncology departments of 2 Institutions from January 2013 
to January 2017 was available. Median follow-up was 13 
months (range, 0.1-45 months). Thirty-two percent of 
patients (N=109) had baseline CVD. Specifically, 29 
patients (27%) had arrhythmia, 10 (9%) hypertensive CVD, 
9 (8%) heart failure, 5 (5%) valvulopathy,  40 (37%) 
ischaemic heart disease, and 16 (15%) others.  A total of 
289 patients (82%) were treated with platinum-based 
chemotherapy (CT), 41% of them concomitant with 
radiation therapy (RT); 300 patients (87%) received 
thoracic RT; and 50 (15%) patients underwent surgery. 
Clinical-pathological and therapeutic characteristics were 
assessed for overall survival (OS) as primary endpoint 
using univariate and multivariate COX regression analysis. 
Results  
Our cohort consisted of 305 men (88%) and 40 (12%) 
women, with a median age of 67 years old (range, 31-88 
years). Most of them (70%) had a Karnofsky performance 
status (KPS) ≥80. The most common histologies were 
adenocarcinoma (36%) and squamous cell carcinoma 
(54%). Most of patients were stages IIIA (40%) and IIIB 
(40%). The median radiation dose was 61 Gy (range, 12-
70). Multivariate analyses showed worse OS in patients 
with advanced stages (p=0.009). Patients treated with 
surgery, RT or CT associated with better OS (HR 0.36, 
p<0.001; HR 0.42, p=0.001; HR 0.46, p<0.001, 
respectively). CVD was associated with poorer OS (HR = 
1.44; CI: 1.07-1.93; p=0.016). Additionally, CVD 
associated with a higher risk of distant metastasis (HR = 
1.46; CI: 1.04-2.05; p=0.026). Within the CVD, we 
specifically found that hypertensive CVD and heart failure 
associated with lower OS (HR = 1.92; CI: 1.14-3.24; 
p=0.013) 
Conclusion  
Self-reported CVD is associated with worse OS and higher 
risk of distant metastasis in NSCLC patients. Chronic 
inflammation associated with CVD seems to be a major 
pathophysiologic factor in the development of distant 
metastasis. Our genetic constitution may be crucial for 
the susceptibility of a distinct inflammation, a task for 
future studies. 
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Purpose or Objective  
Radiation-induced pneumonitis (RP) is a serious 
complication after lung cancer radiotherapy. Several 
studies have seen that keeping V5<60-65% plays a very 
important role in preventing this unwanted effect and 
has been established as predictive of RP incidence.  
The purpose of this work is to analyse lung dose-volume 
data, evaluate our degree of V5 compliance and the 
incidence of RP in our patients.Material and Methods  
We retrospectively selected 114 patients who underwent 
3D-CRT for locoregional advanced lung cancer in our 
centre from January 2014 to September 2017. The 
patients were treated with radiotherapy alone, 
